Star Therapeutics Raises $200 Million

<p><strong>SOUTH SAN FRANCISCO&comma; CA<&sol;strong> – <a href&equals;"https&colon;&sol;&sol;star-therapeutics&period;com&sol;" target&equals;"&lowbar;blank" rel&equals;"noopener">Star Therapeutics<&sol;a>&comma; a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need&comma; today announced a &dollar;200 million private financing&period; The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors&comma; with participation from Agent Capital&comma; Catalio Capital Management&comma; Cormorant Asset Management&comma; New Leaf Venture Partners&comma; NYBC Ventures&comma; RA Capital Management&comma; Redmile&comma; Sofinnova Investments&comma; Soleus Capital&comma; and a leading sovereign wealth fund&period; Proceeds from the private financing will support Star’s next-generation pipeline of potential best-in-disease therapies&comma; advancing its current preclinical programs into the clinic and expanding its pipeline with additional programs&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Our mission is to develop best-in-disease therapies at scale for the millions of patients with diseases of significant unmet need&comma;” said Adam Rosenthal&comma; Ph&period;D&period;&comma; founder and chief executive officer of Star Therapeutics&period; &OpenCurlyDoubleQuote;This financing marks the next phase for Star&comma; building on our team’s track record of discovering and developing novel medicines&period; With an experienced team&comma; a growing pipeline and the support of a top-tier investor base&comma; we are well positioned to advance our current programs into the clinic and continue to add new&comma; highly innovative programs to our pipeline in order to meaningfully improve patient outcomes&period;”<&sol;p>&NewLine;<p>Across multiple companies&comma; members of the Star team have invented four first-in-class therapies that are now in Phase 3 development or commercialized&period; The team has contributed to four successful acquisitions&comma; including Vega Therapeutics&comma; DICE Therapeutics&comma; True North Therapeutics and iPierian&period; In July 2026&comma; Incyte completed the <a href&equals;"https&colon;&sol;&sol;investor&period;incyte&period;com&sol;news-releases&sol;news-release-details&sol;incyte-acquire-vega-therapeutics-wholly-owned-subsidiary-star" target&equals;"&lowbar;blank" rel&equals;"noopener">acquisition<&sol;a> of Star’s wholly owned subsidiary Vega Therapeutics in a transaction valued at up to &dollar;2 billion&comma; which included Star’s lead program latarcibart &lpar;VGA039&rpar;&comma; a novel monoclonal antibody in Phase 3 development for von Willebrand disease&period; Additionally&comma; in September 2026&comma; Star’s spinout company Electra Therapeutics became a publicly traded company &lpar;Nasdaq&colon; ETRA&rpar;&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;I have worked with this team across three different companies&comma; and have seen firsthand their ability to identify important therapeutic opportunities and translate them into medicines with the potential to make an impact for patients&comma;” said Carl L&period; Gordon&comma; Ph&period;D&period;&comma; CFA&comma; managing partner at OrbiMed&period; &OpenCurlyDoubleQuote;We believe Star has the team&comma; scientific approach and pipeline to build on those achievements in its next phase of growth&period;”<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Star stood out to us because of the strength of its team and its proven ability to invent and develop innovative therapies&comma;” said Vish Sridharan&comma; M&period;D&period;&comma; assistant portfolio manager and research analyst at Janus Henderson Investors&comma; who is joining as a board observer for Star Therapeutics&period; &OpenCurlyDoubleQuote;We do not often invest in companies at this stage of development&comma; which reflects our conviction in Star’s ability to repeatedly identify areas of significant unmet need and develop differentiated therapies to address them&period; We look forward to supporting the team as it advances its growing pipeline into the clinic and continues to develop the next generation of therapies for patients&period;”<&sol;p>&NewLine;